Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Cognex Corporation

15.8% sales growth and 13.64% return on equity

Cognex Corporation provides machine vision products that capture and analyze visual information in order to automate manufacturing and distribution tasks worldwide.

Cognex Corporation’s sales growth this year is expected to be 9.1% and 11.7% for next year.

Year-on-year quarterly revenue growth grew by 37%, now sitting on 757.17M for the twelve trailing months.

Cognex Corporation’s sales growth for the next quarter is 15.8%. The company’s growth estimates for the ongoing quarter and the next is 145.5% and 83.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.64%.

Volatility

Cognex Corporation’s last day, last week, and last month’s average volatility was a negative 0.75%, a negative 0.41%, and a positive 0.26%, respectively.

Cognex Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 1.39%, 2.20%, and 2.51%, respectively.

Cognex Corporation’s Stock Yearly Top and Bottom Value

Cognex Corporation’s stock is valued at $80.29 at 22:22 EST, under its 52-week high of $83.10 and way above its 52-week low of $35.20.

Cognex Corporation’s Moving Average

Cognex Corporation’s value is higher than its 50-day moving average of $76.32 and way higher than its 200-day moving average of $67.74.

2. T

71% sales growth and 5.95% return on equity

T-Mobile US, Inc., through its subsidiaries, provides wireless services for branded postpaid and prepaid, and wholesale customers in the United States, Puerto Rico, and the United States Virgin Islands.

T’s sales growth this year is expected to be 50.3% and 15.4% for next year.

Year-on-year quarterly revenue growth grew by 74.2%, now sitting on 59.93B for the twelve trailing months.

T’s sales growth for the next quarter is 71%. The company’s growth estimates for the ongoing quarter and the next is a negative 43.7% and negative -42.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.95%.

Volatility

T’s last day, last week, and last month’s average volatility was 0.11%, 0.16%, and 0.01%, respectively.

T’s last day, last week, and last month’s high and low average amplitude percentage was 1.00%, 1.55%, and 1.59%, respectively.

T’s Stock Yearly Top and Bottom Value

T’s stock is valued at $133.49 at 22:22 EST, under its 52-week high of $134.76 and way above its 52-week low of $63.50.

T’s Moving Average

T’s value is above its 50-day moving average of $130.62 and way higher than its 200-day moving average of $116.09.

Previous days news about T

Y-biologics signed license agreement with 3d medicines for T cell bispecific engager in greater China territory. According to Business Insider on Tuesday, 5 January, "Following early work in discovery, the novel bispecific platform technology ALiCE, allows effective redirection of T cells onto tumor cells and thereby specifically kill the tumor cells giving very potent and long-lasting efficacy in the treatment of cancer patients. ", "The technology is the CD3-based bispecific antibody engineered to have a unique 2 versus 1 structure with two Fab regions targeting for a tumor antigen and Fv region specific for CD3 by placing between T cell and cancer cell. "

IPO lockup expiration alert: poseida therapeutics (pstx). According to Business Insider on Wednesday, 6 January, "Last October, Poseida signed a collaboration agreement with TScan Therapeutics to explore developing allogeneic T cell receptor therapies for the treatment of COVID-19."

Nature methods selects spatially-resolved transcriptomics as the method of the year for 2020. According to Business Insider on Wednesday, 6 January, "This new technology will provide a quantum step forward in our ability to improve responses to CAR T-cell therapies in patients with solid tumors as well as improve outcomes with commercially approved CAR T for hematologic malignancies. "

These are the high-growth themes of 2021 and the etfs that can deliver big gains. According to MarketWatch on Wednesday, 6 January, "The real opportunity here for investors is that obsolete telecom infrastructure necessarily means big business for firms helping the likes of AT&T T and Verizon VZ upgrade their networks. "

3. Neurocrine Biosciences, Inc.

19% sales growth and 13.55% return on equity

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States.

Neurocrine Biosciences, Inc.’s sales growth this year is expected to be 35.2% and 17.6% for next year.

Year-on-year quarterly revenue growth grew by 16.4%, now sitting on 1.04B for the twelve trailing months.

Neurocrine Biosciences, Inc.’s sales growth for the next quarter is 19%. The company’s growth estimates for the current quarter and the next is 68.6% and 28.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.55%.

Volatility

Neurocrine Biosciences, Inc.’s last day, last week, and last month’s average volatility was a positive 0.41%, a negative 0.44%, and a positive 0.05%, respectively.

Neurocrine Biosciences, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.55%, 2.83%, and 3.22%, respectively.

Neurocrine Biosciences, Inc.’s Stock Yearly Top and Bottom Value

Neurocrine Biosciences, Inc.’s stock is valued at $95.85 at 22:34 EST, way under its 52-week high of $136.26 and way higher than its 52-week low of $72.14.

Neurocrine Biosciences, Inc.’s Moving Average

Neurocrine Biosciences, Inc.’s value is higher than its 50-day moving average of $94.64 and way under its 200-day moving average of $107.62.

4. Seattle Genetics, Inc.

60.8% sales growth and 23.4% return on equity

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

Seattle Genetics, Inc.’s sales growth this year is anticipated to be 135.3% and a negative 16.9% for next year.

Year-on-year quarterly revenue growth grew by 397.9%, now sitting on 1.86B for the twelve trailing months.

Seattle Genetics, Inc.’s sales growth for the next quarter is 60.8%. The company’s growth estimates for the present quarter and the next is 507.1% and 72.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.4%.

Volatility

Seattle Genetics, Inc.’s last day, last week, and last month’s average volatility was a negative 4.89%, a negative 1.79%, and a negative 0.06%, respectively.

Seattle Genetics, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 5.97%, 3.42%, and 3.07%, respectively.

Seattle Genetics, Inc.’s Stock Yearly Top and Bottom Value

Seattle Genetics, Inc.’s stock is valued at $175.14 at 22:34 EST, way under its 52-week high of $213.94 and way above its 52-week low of $90.57.

Seattle Genetics, Inc.’s Moving Average

Seattle Genetics, Inc.’s worth is below its 50-day moving average of $182.31 and below its 200-day moving average of $176.02.

5. Middlefield Banc Corp.

9.5% sales growth and 6.48% return on equity

Middlefield Banc Corp. operates as the bank holding company for The Middlefield Banking Company that provides various commercial banking services to small and medium-sized businesses, professionals, small business owners, and retail customers in northeastern and central Ohio.

Middlefield Banc Corp.’s sales growth this year is expected to be 9% and a negative 4.4% for next year.

Year-on-year quarterly revenue growth declined by 21%, now sitting on 39.91M for the twelve trailing months.

Middlefield Banc Corp.’s sales growth for the next quarter is 9.5%. The company’s growth estimates for the present quarter and the next is 4.1% and 162.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.48%.

Volatility

Middlefield Banc Corp.’s last day, last week, and last month’s average volatility was a negative 0.31%, a positive 0.78%, and a positive 0.02%, respectively.

Middlefield Banc Corp.’s last day, last week, and last month’s high and low average amplitude percentage was 1.72%, 3.65%, and 4.39%, respectively.

Middlefield Banc Corp.’s Stock Yearly Top and Bottom Value

Middlefield Banc Corp.’s stock is valued at $22.50 at 22:34 EST, way under its 52-week high of $26.47 and way higher than its 52-week low of $12.00.

Middlefield Banc Corp.’s Moving Average

Middlefield Banc Corp.’s value is above its 50-day moving average of $21.78 and way higher than its 200-day moving average of $19.90.

6. Southside Bancshares, Inc.

7.4% sales growth and 8.48% return on equity

Southside Bancshares, Inc. operates as the bank holding company for Southside Bank that provides a range of financial services to individuals, businesses, municipal entities, and nonprofit organizations.

Southside Bancshares, Inc.’s sales growth this year is anticipated to be 12.7% and a negative 2.2% for next year.

Year-on-year quarterly revenue growth grew by 19%, now sitting on 202.78M for the twelve trailing months.

Southside Bancshares, Inc.’s sales growth for the next quarter is 7.4%. The company’s growth estimates for the present quarter and the next is 25.5% and 408.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.48%.

Volatility

Southside Bancshares, Inc.’s last day, last week, and last month’s average volatility was a positive 0.49%, a negative 0.17%, and a positive 0.16%, respectively.

Southside Bancshares, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.13%, 2.45%, and 2.23%, respectively.

Southside Bancshares, Inc.’s Stock Yearly Top and Bottom Value

Southside Bancshares, Inc.’s stock is valued at $31.03 at 22:34 EST, way below its 52-week high of $37.74 and way higher than its 52-week low of $23.51.

Southside Bancshares, Inc.’s Moving Average

Southside Bancshares, Inc.’s value is higher than its 50-day moving average of $30.84 and way higher than its 200-day moving average of $27.85.

7. American Tower Corporation

6.9% sales growth and 34.18% return on equity

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of approximately 181,000 communications sites.

American Tower Corporation’s sales growth this year is anticipated to be 5.1% and 7.5% for next year.

Year-on-year quarterly revenue growth grew by 3%, now sitting on 7.84B for the twelve trailing months.

American Tower Corporation’s sales growth for the next quarter is 6.9%. The company’s growth estimates for the current quarter and the next is a negative 0% and 48.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.18%.

Volatility

American Tower Corporation’s last day, last week, and last month’s average volatility was a positive 1.11%, a negative 0.04%, and a negative 0.25%, respectively.

American Tower Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 1.85%, 1.78%, and 1.99%, respectively.

American Tower Corporation’s Stock Yearly Top and Bottom Value

American Tower Corporation’s stock is valued at $221.07 at 22:34 EST, way under its 52-week high of $272.20 and way above its 52-week low of $174.32.

American Tower Corporation’s Moving Average

American Tower Corporation’s value is below its 50-day moving average of $228.26 and under its 200-day moving average of $245.21.

8. Citizens & Northern Corp

31.7% sales growth and 6.64% return on equity

Citizens & Northern Corporation operates as the bank holding company for Citizens & Northern Bank that provides a range of banking and mortgage services to individual and corporate customers in North Central Pennsylvania and Southern New York.

Citizens & Northern Corp’s sales growth this year is anticipated to be 23% and 7.7% for next year.

Year-on-year quarterly revenue growth grew by 34.5%, now sitting on 81.03M for the twelve trailing months.

Citizens & Northern Corp’s sales growth for the next quarter is 31.7%. The company’s growth estimates for the present quarter and the next is a negative 8.7% and negative -7.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.64%.

Volatility

Citizens & Northern Corp’s last day, last week, and last month’s average volatility was 2.11%, 0.66%, and 0.40%, respectively.

Citizens & Northern Corp’s last day, last week, and last month’s high and low average amplitude percentage was 3.42%, 2.06%, and 2.97%, respectively.

Citizens & Northern Corp’s Stock Yearly Top and Bottom Value

Citizens & Northern Corp’s stock is valued at $19.84 at 22:34 EST, way below its 52-week high of $28.87 and way above its 52-week low of $14.92.

Citizens & Northern Corp’s Moving Average

Citizens & Northern Corp’s value is higher than its 50-day moving average of $19.24 and higher than its 200-day moving average of $18.21.

LEAVE A REPLY

Please enter your comment!
Please enter your name here